{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T20:46:32Z","timestamp":1649105192822},"reference-count":42,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2017.0597","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:29:13Z","timestamp":1525253353000},"source":"Crossref","is-referenced-by-count":1,"title":["Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk"],"prefix":"10.3238","author":[{"given":"Marcus-Alexander","family":"W\u00f6rns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Robert","family":"Galle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Manns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2017,9,4]]},"reference":[{"key":"10.3238\/arztebl.2017.0597_ref1","unstructured":"World Health Organization: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx (last accessed on 20 June 2017)."},{"key":"10.3238\/arztebl.2017.0597_ref2","doi-asserted-by":"crossref","unstructured":"Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl. 1): 20\u201337","DOI":"10.1016\/j.jhep.2008.01.022"},{"key":"10.3238\/arztebl.2017.0597_ref3","doi-asserted-by":"crossref","unstructured":"Xu F, Moorman AC, Tong X, et al.: All-cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus. Clin Infect Dis 2016; 62: 289\u201397","DOI":"10.1093\/cid\/civ860"},{"key":"10.3238\/arztebl.2017.0597_ref4","doi-asserted-by":"crossref","unstructured":"Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825\u201332","DOI":"10.1016\/S0140-6736(96)07642-8"},{"key":"10.3238\/arztebl.2017.0597_ref5","doi-asserted-by":"crossref","unstructured":"Sarrazin C, Berg T, Ross RS, et al.: [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol 2010; 48: 289\u2013351","DOI":"10.1055\/s-0028-1110008"},{"key":"10.3238\/arztebl.2017.0597_ref6","unstructured":"Greten TF, Malek NP, Schmidt S, et al.: [Diagnosis of and therapy for hepatocellular carcinoma]. Z Gastroenterol 2013; 51: 1269\u2013326"},{"key":"10.3238\/arztebl.2017.0597_ref7","doi-asserted-by":"crossref","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, et al.: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584\u201393","DOI":"10.1001\/jama.2012.144878"},{"key":"10.3238\/arztebl.2017.0597_ref8","doi-asserted-by":"crossref","unstructured":"Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y: Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329\u201337","DOI":"10.7326\/0003-4819-158-5-201303050-00005"},{"key":"10.3238\/arztebl.2017.0597_ref9","doi-asserted-by":"crossref","unstructured":"Colombo M, Iavarone M: Role of antiviral treatment for HCC prevention. Best Pract Res Clin Gastroenterol 2014; 28: 771\u201381","DOI":"10.1016\/j.bpg.2014.07.017"},{"key":"10.3238\/arztebl.2017.0597_ref10","doi-asserted-by":"crossref","unstructured":"D\u2018Ambrosio R, Della Corte C, Colombo M: Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy. Int J Mol Sci 2015; 16: 19698\u2013712","DOI":"10.3390\/ijms160819698"},{"key":"10.3238\/arztebl.2017.0597_ref11","doi-asserted-by":"crossref","unstructured":"Poynard T, Moussalli J, Munteanu M, et al.: Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013; 59: 675\u201383","DOI":"10.1016\/j.jhep.2013.05.015"},{"key":"10.3238\/arztebl.2017.0597_ref12","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver: EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392\u2013420","DOI":"10.1016\/j.jhep.2013.11.003"},{"key":"10.3238\/arztebl.2017.0597_ref13","doi-asserted-by":"crossref","unstructured":"AASLD\/IDSA HCV Guidance Panel: Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932\u201354","DOI":"10.1002\/hep.27950"},{"key":"10.3238\/arztebl.2017.0597_ref14","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908\u201343","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"10.3238\/arztebl.2017.0597_ref15","doi-asserted-by":"crossref","unstructured":"Imamura H, Matsuyama Y, Tanaka E, et al.: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200\u20137","DOI":"10.1016\/S0168-8278(02)00360-4"},{"key":"10.3238\/arztebl.2017.0597_ref16","doi-asserted-by":"crossref","unstructured":"Singal AK, Freeman DH, Jr., Anand BS: Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 32: 851\u20138","DOI":"10.1111\/j.1365-2036.2010.04414.x"},{"key":"10.3238\/arztebl.2017.0597_ref17","doi-asserted-by":"crossref","unstructured":"Zeuzem S: Treatment options in hepatitis C\u2014the current state of the art. Dtsch Arztebl Int 2017; 114: 11\u201321","DOI":"10.3238\/arztebl.2017.0011"},{"key":"10.3238\/arztebl.2017.0597_ref18","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Suzuki F, Fujiyama S, et al.: Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 2017; 89: 476\u201383","DOI":"10.1002\/jmv.24663"},{"key":"10.3238\/arztebl.2017.0597_ref19","unstructured":"European Medicines Agency: Minutes of the pharmacovigilance risk assessment committee (PRAC) meeting on 11\u201314 April 2016. www.ema.europa.eu\/docs\/en_GB\/document_library\/ (last accessed on 20 June 2017)."},{"key":"10.3238\/arztebl.2017.0597_ref20","doi-asserted-by":"crossref","unstructured":"Conti F, Buonfiglioli F, Scuteri A, et al.: Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65: 727\u201333","DOI":"10.1016\/j.jhep.2016.06.015"},{"key":"10.3238\/arztebl.2017.0597_ref21","doi-asserted-by":"crossref","unstructured":"Kozbial K, Moser S, Schwarzer R, et al.: Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016; 65: 856\u20138","DOI":"10.1016\/j.jhep.2016.06.009"},{"key":"10.3238\/arztebl.2017.0597_ref22","doi-asserted-by":"crossref","unstructured":"Cardoso H, Vale AM, Rodrigues S, et al.: High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 2016; 65: 1070\u20131","DOI":"10.1016\/j.jhep.2016.07.027"},{"key":"10.3238\/arztebl.2017.0597_ref23","doi-asserted-by":"crossref","unstructured":"Cheung MC, Walker AJ, Hudson BE, et al.: Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 65: 741\u20137","DOI":"10.1016\/j.jhep.2016.06.019"},{"key":"10.3238\/arztebl.2017.0597_ref24","doi-asserted-by":"crossref","unstructured":"Reig M, Marino Z, Perello C, et al.: Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65: 719\u201326","DOI":"10.1016\/j.jhep.2016.04.008"},{"key":"10.3238\/arztebl.2017.0597_ref25","doi-asserted-by":"crossref","unstructured":"Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD: Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 2016; 65: 859\u201360","DOI":"10.1016\/j.jhep.2016.06.023"},{"key":"10.3238\/arztebl.2017.0597_ref26","doi-asserted-by":"crossref","unstructured":"Zavaglia C, Okolicsanyi S, Cesarini L, et al.: Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol 2017; 66: 236\u20137","DOI":"10.1016\/j.jhep.2016.08.016"},{"key":"10.3238\/arztebl.2017.0597_ref27","doi-asserted-by":"crossref","unstructured":"Minami T, Tateishi R, Nakagomi R, et al.: The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol 2016; 65: 1272\u20133","DOI":"10.1016\/j.jhep.2016.07.043"},{"key":"10.3238\/arztebl.2017.0597_ref28","doi-asserted-by":"crossref","unstructured":"ANRS Collaborative Study Group on Hepatocellular Carcinoma: Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016; 65: 734\u201340","DOI":"10.1016\/j.jhep.2016.05.045"},{"key":"10.3238\/arztebl.2017.0597_ref29","doi-asserted-by":"crossref","unstructured":"Bruix J, Takayama T, Mazzaferro V, et al.: Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344\u201354","DOI":"10.1016\/S1470-2045(15)00198-9"},{"key":"10.3238\/arztebl.2017.0597_ref30","doi-asserted-by":"crossref","unstructured":"Clavien PA, Lesurtel M, Bossuyt PM, et al.: Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11\u201322","DOI":"10.1016\/S1470-2045(11)70175-9"},{"key":"10.3238\/arztebl.2017.0597_ref31","doi-asserted-by":"crossref","unstructured":"Llovet JM, Villanueva A: Liver cancer: effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol Hepatol 2016; 13: 561\u20132","DOI":"10.1038\/nrgastro.2016.140"},{"key":"10.3238\/arztebl.2017.0597_ref32","doi-asserted-by":"crossref","unstructured":"El-Serag HB, Kanwal F, Richardson P, Kramer J: Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology 2016; 64: 130\u20137","DOI":"10.1002\/hep.28535"},{"key":"10.3238\/arztebl.2017.0597_ref33","doi-asserted-by":"crossref","unstructured":"Toyoda H, Kumada T, Tada T: Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Abstract. Hepatology 2016; 64: 1818\u20139","DOI":"10.1002\/hep.28632"},{"key":"10.3238\/arztebl.2017.0597_ref34","doi-asserted-by":"crossref","unstructured":"Camma C, Cabibbo G, Craxi A: Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol 2016; 65: 861\u20132","DOI":"10.1016\/j.jhep.2016.04.033"},{"key":"10.3238\/arztebl.2017.0597_ref35","doi-asserted-by":"crossref","unstructured":"Meissner EG, Wu D, Osinusi A, et al.: Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014; 124: 3352\u201363","DOI":"10.1172\/JCI75938"},{"key":"10.3238\/arztebl.2017.0597_ref36","doi-asserted-by":"crossref","unstructured":"Serti E, Chepa-Lotrea X, Kim YJ, et al.: Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 2015; 149: 190\u2013200","DOI":"10.1053\/j.gastro.2015.03.004"},{"key":"10.3238\/arztebl.2017.0597_ref37","doi-asserted-by":"crossref","unstructured":"Villani R, Facciorusso A, Bellanti F, et al.: DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor tisk during anti-HCV treatment. PLoS One 2016; 11: e0167934","DOI":"10.1371\/journal.pone.0167934"},{"key":"10.3238\/arztebl.2017.0597_ref38","doi-asserted-by":"crossref","unstructured":"Lok AS, Everhart JE, Wright EC, et al.: Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140: 840\u20139; quiz e12","DOI":"10.1053\/j.gastro.2011.01.021"},{"key":"10.3238\/arztebl.2017.0597_ref39","doi-asserted-by":"crossref","unstructured":"Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L: Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol 2017; 66: 1173\u201381","DOI":"10.1016\/j.jhep.2017.01.020"},{"key":"10.3238\/arztebl.2017.0597_ref40","doi-asserted-by":"crossref","unstructured":"Fernandez Carrillo C, Lens S, Llop E, et al.: Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: analysis of data from the hepa-C registry. Hepatology 2017; 65:1810\u201322","DOI":"10.1002\/hep.29097"},{"key":"10.3238\/arztebl.2017.0597_ref41","doi-asserted-by":"crossref","unstructured":"Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A: Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment. J Hepatol 2016; 65: 862\u20134","DOI":"10.1016\/j.jhep.2016.05.034"},{"key":"10.3238\/arztebl.2017.0597_ref42","doi-asserted-by":"crossref","unstructured":"Zeng QL, Li ZQ, Liang HX, et al.: Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? J Hepatol 2016; 65: 1068\u20139","DOI":"10.1016\/j.jhep.2016.07.029"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T10:32:48Z","timestamp":1638873168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,4]]},"references-count":42,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2017.0597","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,4]]}}}